Literature DB >> 1722219

Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients.

C Bleul1, M Müller, R Frank, H Gausepohl, U Koldovsky, H N Mgaya, J Luande, M Pawlita, J ter Meulen, R Viscidi.   

Abstract

Antibody-reactive regions on the human papillomavirus type 18 (HPV-18) E6 and E7 proteins were identified with rabbit polyclonal anti-fusion protein sera by screening of an fd phage expression library containing subgenomic HPV-18 DNA fragments and by testing of overlapping decapeptides representing the E6 and E7 open reading frames. Peptides comprising the delineated regions (designated E6/1 to E6/4 and E7/1) were synthesized and used in an enzyme-linked immunosorbent assay (ELISA) to detect anti-HPV-18 antibodies in human sera. A total of 232 human serum samples (identical numbers of cervical cancer patients and age-matched controls) collected in Tanzania were tested. Similar prevalences (between 0.8 and 4.3%) of antibodies recognizing the different E6 peptides were found in the sera from tumor patients and controls. With a synthetic 28-mer peptide (designated pepE701) comprising the E7/1 region, a significant difference was found: 10 of 116 tumor serum samples but 0 of 116 control serum samples showed a specific reaction (P less than 0.001). This observation confirms earlier results with HPV-16 E7 fusion proteins (I. Jochmus-Kudielka, A. Schneider, R. Braun, R. Kimmig, U. Koldovsky, K. E. Schneweis, K. Seedorf, and L. Gissmann, J. Natl. Cancer Inst. 81:1698-1704, 1989). A lower prevalence of anti-HPV-18 E7 antibodies was observed when 188 human serum samples collected in Germany from tumor patients and controls were tested (3 of 94 positive in the cancer group; 0 of 94 positive in the control group). The type specificity of anti-HPV-18 E7 antibodies was demonstrated when the HPV type found by Southern hybridization in the cervical cancer biopsies was compared with seroreactivity: 4 of 8 serum samples obtained from HPV-18 DNA-positive but 0 of 16 serum samples from HPV-18 DNA-negative tumor patients reacted in the HPV-18 E7 ELISA. In addition, HPV-18-positive sera failed to react in a peptide ELISA with the homologous HPV-16 E7 region (M. Müller, H. Gausepohl, G. de Martinoff, R. Frank, R. Brasseur, and L. Gissmann, J. Gen. Virol. 71:2709-2717, 1990) and vice versa.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722219      PMCID: PMC270166          DOI: 10.1128/jcm.29.8.1579-1588.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Oncogenic association of specific human papillomavirus types with cervical neoplasia.

Authors:  A T Lorincz; G F Temple; R J Kurman; A B Jenson; W D Lancaster
Journal:  J Natl Cancer Inst       Date:  1987-10       Impact factor: 13.506

2.  Identification of B-epitopes in the human papillomavirus 18 E7 open reading frame protein.

Authors:  L A Selvey; R W Tindle; H M Geysen; C J Haller; J A Smith; I H Frazer
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

3.  Skin test for HPV type 16 proteins in cervical intraepithelial neoplasia.

Authors:  R Höpfl; M Sandbichler; N Sepp; K Heim; E Müller-Holzner; B Wartusch; O Dapunt; I Jochmus-Kudielka; J ter Meulen; L Gissmann
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

4.  Locally most powerful tests for detecting treatment effects when only a subset of patients can be expected to "respond" to treatment.

Authors:  W J Conover; D S Salsburg
Journal:  Biometrics       Date:  1988-03       Impact factor: 2.571

5.  Host specificity of DNA produced by Escherichia coli: bacterial mutations affecting the restriction and modification of DNA.

Authors:  W B Wood
Journal:  J Mol Biol       Date:  1966-03       Impact factor: 5.469

6.  Loss of MHC class-I expression in cervical carcinomas.

Authors:  M E Connor; P L Stern
Journal:  Int J Cancer       Date:  1990-12-15       Impact factor: 7.396

7.  Human papillomavirus deoxyribonucleic acid in adenocarcinoma and adenosquamous carcinoma of the uterine cervix.

Authors:  D Smotkin; J S Berek; Y S Fu; N F Hacker; F J Major; F O Wettstein
Journal:  Obstet Gynecol       Date:  1986-08       Impact factor: 7.661

Review 8.  Cachectin and tumour necrosis factor as two sides of the same biological coin.

Authors:  B Beutler; A Cerami
Journal:  Nature       Date:  1986 Apr 17-23       Impact factor: 49.962

9.  Possible prognostic significance of human papillomavirus type in cervical cancer.

Authors:  W Barnes; G Delgado; R J Kurman; E S Petrilli; D M Smith; S Ahmed; A T Lorincz; G F Temple; A B Jenson; W D Lancaster
Journal:  Gynecol Oncol       Date:  1988-03       Impact factor: 5.482

10.  Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins.

Authors:  S A Jenison; J M Firzlaff; A Langenberg; D A Galloway
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

View more
  10 in total

1.  Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer.

Authors:  W Meschede; K Zumbach; J Braspenning; M Scheffner; L Benitez-Bribiesca; J Luande; L Gissmann; M Pawlita
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

2.  T-cell response to cottontail rabbit papillomavirus structural proteins in infected rabbits.

Authors:  R Selvakumar; L A Borenstein; Y L Lin; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

Review 3.  Pathogenesis of genital HPV infection.

Authors:  A Schneider
Journal:  Genitourin Med       Date:  1993-06

4.  Human papillomavirus type 18 E6*, E6, and E7 protein synthesis in cell-free translation systems and comparison of E6 and E7 in vitro translation products to proteins immunoprecipitated from human epithelial cells.

Authors:  B Roggenbuck; P M Larsen; S J Fey; D Bartsch; L Gissmann; E Schwarz
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

Review 5.  Antigen-specific immunotherapy of cervical and ovarian cancer.

Authors:  Chien-Fu Hung; T C Wu; Archana Monie; Richard Roden
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

6.  Antibodies against papillomavirus antigens in cervical secretions from condyloma patients.

Authors:  L Dillner; A Fredriksson; E Persson; O Forslund; B G Hansson; J Dillner
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

7.  A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.

Authors:  Alberto Monroy-García; Miguel A Gómez-Lim; Benny Weiss-Steider; Georgina Paz-de la Rosa; Jorge Hernández-Montes; Karyna Pérez-Saldaña; Yessica S Tapia-Guerrero; Mariel E Toledo-Guzmán; Edelmiro Santiago-Osorio; Héctor I Sanchez-Peña; María de Lourdes Mora-García
Journal:  Virol J       Date:  2011-02-09       Impact factor: 4.099

8.  Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58.

Authors:  Wan-Xiang Xu; Jian Wang; Hai-Ping Tang; Ya-Ping He; Qian-Xi Zhu; Satish K Gupta; Shao-Hua Gu; Qiang Huang; Chao-Neng Ji; Ling-Feng Liu; Gui-Ling Li; Cong-Jian Xu; Yi Xie
Journal:  Sci Rep       Date:  2016-10-06       Impact factor: 4.379

9.  Validation of Serological Antibody Profiles Against Human Papillomavirus Type 16 Antigens as Markers for Early Detection of Cervical Cancer.

Authors:  Dolores Azucena Salazar-Piña; Adolfo Pedroza-Saavedra; Aurelio Cruz-Valdez; Eduardo Ortiz-Panozo; Minerva Maldonado-Gama; Lilia Chihu-Amparan; Angelica Nallelhy Rodriguez-Ocampo; Emilia Orozco-Fararoni; Fernando Esquivel-Guadarrama; Lourdes Gutierrez-Xicotencatl
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

10.  A simpler and more cost-effective peptide biosynthetic method using the truncated GST as carrier for epitope mapping.

Authors:  Wan-Xiang Xu; Jian Wang; Hai-Ping Tang; Ling-Han Chen; Wen-Bo Lian; Jian-Min Zhan; Satish K Gupta; Chao-Neng Ji; Shao-Hua Gu; Yi Xie
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.